Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2003 May;48(5):760-7.

Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.

Author information

  • 1University of California, Irvine, USA.

Abstract

BACKGROUND:

Tazarotene in a gel formulation is widely used in the treatment of psoriasis.

OBJECTIVE:

To determine the efficacy and safety of tazarotene 0.1% and 0.05% creams in the treatment of psoriasis.

METHODS:

A total of 1303 patients participated in 2 clinical trials. Patients applied tazarotene creams 0.1% and 0.05% or vehicle once daily to all psoriatic lesions for 12 weeks followed by a 12-week posttreatment period.

RESULTS:

Both creams were significantly more effective than vehicle on the basis of an overall assessment of psoriasis, a global response to treatment, and reduction in plaque elevation and scaling. Therapeutic effect was maintained during the posttreatment period. Common adverse events included signs and symptoms of skin irritation.

CONCLUSION:

Tazarotene creams were associated with significant reductions in the severity of the clinical signs of psoriasis and were found to be safe with acceptable tolerability. Tazarotene cream 0.1% was generally more effective, although slightly less well tolerated, than the 0.05% cream.

PMID:
12734506
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk